Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif. – Nov. 5, 2020 – Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended September 30, 2020 and provided a corporate update.
“In the third quarter we focused on preparing to initiate two clinical trials for MarzAA and building our complement programs. We plan to enroll patients in a pivotal Phase 3 study of MarzAA for the treatment of bleeding in hemophilia A or B patients with inhibitors and initiate a Phase 1/2 trial of MarzAA for the treatment of bleeding in Factor VII Deficiency, Glanzmann thrombasthenia, and Hemlibra patients by the end of the year”, said Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences. “In addition, we are on track to deliver on other important program milestones including disclosing a development candidate for our systemic complement program this year.”
Recent Milestones:
- Complement intellectual property: The United States Patent and Trademark Offices issued a patent covering Catalyst’s portfolio of engineered proteases that selectively cleave and degrade complement factor 3 (C3), including the lead candidate CB 2782-PEG, a potential best-in-class treatment for dry AMD currently under development under a license and collaboration agreement with Biogen. These modified proteases inhibit complement activation and have the potential to treat multiple diseases in which complement activation plays a role. The newly issued patent provides protection until at least 2038.
Expected Milestones:
- Marzeptacog alfa (activated) – MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa):
- Enroll the first patient in a Phase 3 open-label trial before the end of the year, evaluating the efficacy of SQ MarzAA to treat episodic bleeding in individuals with hemophilia A or B with inhibitors, and
- Initiate a Phase 1/2 trial in FVII Deficiency, Glanzmann Thrombasthenia, and Hemlibra patients before year-end.
- Systemic complement: Announce a development candidate in December 2020.
Third Quarter 2020 Results and Financial Highlights:
- Cash, cash equivalents and, investments, as of September 30, were $104.1 million.
- General and administrative expenses were $3.8 million and $3.3 million during the three months ended September 30, 2020 and 2019, respectively, an increase of $0.5 million, or 17%. The increase was due primarily to an increase of $0.4 million in professional services and an increase of $0.4 million in payroll and payroll related costs, partially offset by a decrease of $0.2 million in indirect employee and facilities costs.
- Interest and other income, net was $0.1 million and $0.5 million during the three months ended September 30, 2020 and 2019, respectively, a decrease of $0.4 million. The decrease was primarily due to a decrease in interest income on investments.
- As of September 30, 2020, the Company had 22,082,924 shares of common stock outstanding.
About Catalyst Biosciences
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare hematologic and complement-mediated disorders. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about Catalyst’s plans to enroll the first patient in a Phase 3 open-label trial of MarzAA and initiate a Phase 1/2 trial of MarzAA in FVII Deficiency, Glanzmann Thrombasthenia, and Hemlibra patients before year-end, the potential for MarzAA to effectively and therapeutically treat hemophilia subcutaneously, the superiority of CB 2679d-GT over other gene therapy candidates and the Company’s collaboration with Biogen for the development and commercialization of pegylated CB 2782 for the potential treatment of geographic atrophy-associated dry age-related macular degeneration. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of COVID-19 and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of MarzAA, including the generation of neutralizing antibodies, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalyst’s agreement, competition and other risks described in the “Risk Factors” section of the Company’s quarterly report filed with the Securities and Exchange Commission on November 5, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
Contact:
Ana Kapor
Catalyst Biosciences, Inc.
investors@catbio.com
Catalyst Biosciences, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
|
|
|
September 30, 2020 |
|
|
December 31, 2019 |
|
||
|
|
|
(Unaudited) |
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
24,923 |
|
|
$ |
15,369 |
|
|
Short-term investments |
|
|
77,959 |
|
|
|
61,496 |
|
|
Accounts receivable |
|
|
1,555 |
|
|
|
15,000 |
|
|
Prepaid and other current assets |
|
|
3,535 |
|
|
|
4,201 |
|
|
Total current assets |
|
|
107,972 |
|
|
|
96,066 |
|
|
Long-term investments |
|
|
1,171 |
|
|
|
— |
|
|
Other assets, noncurrent |
|
|
698 |
|
|
|
257 |
|
|
Right-of-use assets |
|
|
1,524 |
|
|
|
1,927 |
|
|
Property and equipment, net |
|
|
439 |
|
|
|
304 |
|
|
Total assets |
|
$ |
111,804 |
|
|
$ |
98,554 |
|
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
4,244 |
|
|
$ |
4,279 |
|
|
Accrued compensation |
|
|
2,543 |
|
|
|
2,106 |
|
|
Deferred revenue |
|
|
764 |
|
|
|
15,000 |
|
|
Other accrued liabilities |
|
|
8,750 |
|
|
|
7,031 |
|
|
Operating lease liability |
|
|
519 |
|
|
|
483 |
|
|
Total current liabilities |
|
|
16,820 |
|
|
|
28,899 |
|
|
Operating lease liability, noncurrent |
|
|
925 |
|
|
|
1,319 |
|
|
Total liabilities |
|
|
17,745 |
|
|
|
30,218 |
|
|
Stockholders’ equity: |
|
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued and outstanding |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.001 par value, 100,000,000 shares authorized; 22,082,924 and 12,040,835 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively |
|
|
22 |
|
|
|
12 |
|
|
Additional paid-in capital |
|
|
389,883 |
|
|
|
326,810 |
|
|
Accumulated other comprehensive income |
|
|
8 |
|
|
|
34 |
|
|
Accumulated deficit |
|
|
(295,854 |
) |
|
|
(258,520 |
) |
|
Total stockholders’ equity |
|
|
94,059 |
|
|
|
68,336 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
111,804 |
|
|
$ |
98,554 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
Catalyst Biosciences, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
(Unaudited)
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
|
License |
|
$ |
32 |
|
|
$ |
— |
|
|
$ |
15,100 |
|
|
$ |
— |
|
|
Collaboration |
|
|
861 |
|
|
|
— |
|
|
|
3,817 |
|
|
|
— |
|
|
License and collaboration revenue |
|
|
893 |
|
|
|
— |
|
|
|
18,917 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of license |
|
|
32 |
|
|
|
— |
|
|
|
3,102 |
|
|
|
— |
|
|
Cost of collaboration |
|
|
879 |
|
|
|
— |
|
|
|
4,030 |
|
|
|
— |
|
|
Research and development |
|
|
12,249 |
|
|
|
9,927 |
|
|
|
38,419 |
|
|
|
33,066 |
|
|
General and administrative |
|
|
3,833 |
|
|
|
3,268 |
|
|
|
11,895 |
|
|
|
10,224 |
|
|
Total operating expenses |
|
|
16,993 |
|
|
|
13,195 |
|
|
|
57,446 |
|
|
|
43,290 |
|
|
Loss from operations |
|
|
(16,100 |
) |
|
|
(13,195 |
) |
|
|
(38,529 |
) |
|
|
(43,290 |
) |
|
Interest and other income, net |
|
|
67 |
|
|
|
489 |
|
|
|
1,195 |
|
|
|
1,722 |
|
|
Net loss |
|
$ |
(16,033 |
) |
|
$ |
(12,706 |
) |
|
$ |
(37,334 |
) |
|
$ |
(41,568 |
) |
|
Net loss per share attributable to common stockholders, basic and diluted |
|
$ |
(0.73 |
) |
|
$ |
(1.06 |
) |
|
$ |
(2.05 |
) |
|
$ |
(3.47 |
) |
|
Shares used to compute net loss per share attributable to common stockholders, basic and diluted |
|
|
22,072,243 |
|
|
|
12,022,620 |
|
|
|
18,199,575 |
|
|
|
11,992,240 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
